Evidence in Practice: A Review of Real-Life Studies and Clinical Experience with the Preservative-Free Tafluprost (0.0015%) and Timolol (0.5%) Fixed-Dose Combination.

25 When exploring data for the prior latanoprost subgroup in more detail, preserved latanoprost users experienced significant lowering in conjunctival hyperemia severity at each study visit following a switch to PF tafluprost/timolol FC therapy (p<0.001) while, in contrast, reductions in conjunctival hyperemia did not reach statistical significance in the prior PF-latanoprost subgroup (p=0.148). 32 Despite subjective symptoms being generally absent or of mild severity at baseline in the VISIONARY study, severity scores of ocular health indicators were significantly reduced at Month 6, including symptoms of dry eye, irritation, itching, and foreign body sensation (p<0.001 for each parameter). 25 Significant improvements were observed across the VISIONARY study population concerning the severity of corneal fluorescein staining (CFS; Oxford Grade Scale; p<0.0001).

also in 111,027 other papers